Corcept Therapeutics ((CORT)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Corcept Therapeutics is conducting a Phase 2 study titled ‘Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA).’ The study aims to evaluate the efficacy and safety of relacorilant, combined with nab-paclitaxel and bevacizumab, in treating advanced ovarian cancer. This research is significant as it explores potential new treatment combinations for a challenging cancer type.
The study tests the combination of relacorilant, nab-paclitaxel, and bevacizumab. Relacorilant is administered orally, while nab-paclitaxel and bevacizumab are given intravenously. The goal is to assess their combined effectiveness in managing ovarian cancer.
This interventional study follows a single-group model without masking, focusing on treatment. Patients receive the study drugs in a specific sequence and are monitored for efficacy and safety.
The study began on April 11, 2025, with the latest update on June 23, 2025. These dates are crucial as they mark the study’s progress and the availability of updated information.
The study’s progress could influence Corcept Therapeutics’ stock performance by potentially enhancing investor confidence if positive results are reported. This development is also relevant in the context of ongoing advancements in cancer treatment by competitors.
The study is currently recruiting, with further details available on the ClinicalTrials portal.